deucravacitinib,Apremilast
bms,amgen
['psoriasis', 'deucrava', 'deucra', '$bmy']
fda approves $bmy allosteric tyk2 inhibitor sotyktu (deucravacitinib) oral treatment for adults with moderate-to-severe plaque psoriasis without typical jaki blackbox warning: pr: label: 
Biotech Investor